Valued at $50 billion, the Indian pharmaceutical sector continues to grow, fueled by cost efficiency, cutting-edge ...

JP Morgan upgrades Amneal Pharmaceuticals, citing strong Crexont sales, robust generics growth, and a higher 2025 revenue ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

ANI Pharmaceuticals beat Q4 estimates with strong sales growth and raised its 2025 revenue and EPS outlook, driven by ...

The differences between the generics industry and other pharma companies wouldn’t exist without patents – legal titles that exclude others from producing or using an invention or innovation ...

Venus Remedies receives marketing authorization for Sugammadex from Philippines: Our Bureau, Mumbai Tuesday, March 4, 2025, 15:40 Hrs [IST] Venus Remedies Limited, a leading India ...

A Tebra survey found that 84% of Americans believe generic medications are just as effective as their brand-name counterparts ...

Ever bought a pair of ‘abibas’ slides from Pettah? Or some ‘Colvin Klean’ underwear? No harm if you have (reputational harm ...

Venus Remedies receives marketing authorisation for Sugammadex in the Philippines, marking a major step in its expansion into complex generics and the ASEAN market. Sugammadex is a relaxant-binding ...

I asked Sandy, Mira and David for tips to save on prescription drugs. Sandy also highlighted using of generics for easy ...

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue ...